Veracyte | VCYT - Equity Capital And Reserves


Veracyte reported $1.39B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agenus USD -199.08M 22.15M Jun/2026
Agilent USD 7.12B 214M Mar/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Bruker USD 2.5B 46.3M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Illumina USD 2.84B 162M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Siemens EUR 68.26B 3.87B Jun/2026
Sonic Healthcare AUD 8.2B 120.9M Dec/2024
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.39B 44M Jun/2026
Waters USD 15.29B 12.73B Mar/2026